These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
331 related articles for article (PubMed ID: 31370980)
1. A comparison of adherence, outcomes, and costs among opioid use disorder Medicaid patients treated with buprenorphine and methadone: A view from the payer perspective. Kinsky S; Houck PR; Mayes K; Loveland D; Daley D; Schuster JM J Subst Abuse Treat; 2019 Sep; 104():15-21. PubMed ID: 31370980 [TBL] [Abstract][Full Text] [Related]
2. Risk Factors for Relapse and Higher Costs Among Medicaid Members with Opioid Dependence or Abuse: Opioid Agonists, Comorbidities, and Treatment History. Clark RE; Baxter JD; Aweh G; O'Connell E; Fisher WH; Barton BA J Subst Abuse Treat; 2015 Oct; 57():75-80. PubMed ID: 25997674 [TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of Treatments for Opioid Use Disorder. Fairley M; Humphreys K; Joyce VR; Bounthavong M; Trafton J; Combs A; Oliva EM; Goldhaber-Fiebert JD; Asch SM; Brandeau ML; Owens DK JAMA Psychiatry; 2021 Jul; 78(7):767-777. PubMed ID: 33787832 [TBL] [Abstract][Full Text] [Related]
4. Economic evaluation: a comparison of methadone versus buprenorphine for opiate substitution treatment. Maas J; Barton G; Maskrey V; Pinto H; Holland R Drug Alcohol Depend; 2013 Dec; 133(2):494-501. PubMed ID: 23962419 [TBL] [Abstract][Full Text] [Related]
5. Opioid use disorder in Germany: healthcare costs of patients in opioid maintenance treatment. Reimer J; Vogelmann T; Trümper D; Scherbaum N Subst Abuse Treat Prev Policy; 2019 Dec; 14(1):57. PubMed ID: 31842942 [TBL] [Abstract][Full Text] [Related]
6. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York. Neighbors CJ; Choi S; Healy S; Yerneni R; Sun T; Shapoval L Subst Abuse Treat Prev Policy; 2019 Jun; 14(1):28. PubMed ID: 31238952 [TBL] [Abstract][Full Text] [Related]
7. Opioid Overdose After Medication for Opioid Use Disorder Initiation Following Hospitalization or ED Visit. Weiner SG; Little K; Yoo J; Flores DP; Hildebran C; Wright DA; Ritter GA; El Ibrahimi S JAMA Netw Open; 2024 Jul; 7(7):e2423954. PubMed ID: 39037812 [TBL] [Abstract][Full Text] [Related]
8. Healthcare utilization and costs associated with treatment for opioid dependence. Shah A; Duncan M; Atreja N; Tai KS; Gore M J Med Econ; 2018 Apr; 21(4):406-415. PubMed ID: 29320915 [TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder. Wakeman SE; Larochelle MR; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM JAMA Netw Open; 2020 Feb; 3(2):e1920622. PubMed ID: 32022884 [TBL] [Abstract][Full Text] [Related]
10. Management of opioid-dependent patients: comparison of the cost associated with use of buprenorphine/naloxone or methadone, and their interactions with concomitant treatments for infectious or psychiatric comorbidities. Roncero C; Domínguez-Hernández R; Díaz T; Fernández JM; Forcada R; Martínez JM; Seijo P; Terán A; Oyagüez I Adicciones; 2015 Sep; 27(3):179-89. PubMed ID: 26437312 [TBL] [Abstract][Full Text] [Related]
11. Responses among substance abuse treatment providers to the opioid epidemic in the USA: Variations in buprenorphine and methadone treatment by geography, operational, and payment characteristics, 2007-16. Yang JC; Roman-Urrestarazu A; Brayne C PLoS One; 2020; 15(3):e0229787. PubMed ID: 32126120 [TBL] [Abstract][Full Text] [Related]
12. The effect of Medicaid expansion on use of opioid agonist treatment and the role of provider capacity constraints. Gertner AK; Robertson AG; Jones H; Powell BJ; Silberman P; Domino ME Health Serv Res; 2020 Jun; 55(3):383-392. PubMed ID: 32166761 [TBL] [Abstract][Full Text] [Related]
13. Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder. Hadland SE; Bagley SM; Rodean J; Silverstein M; Levy S; Larochelle MR; Samet JH; Zima BT JAMA Pediatr; 2018 Nov; 172(11):1029-1037. PubMed ID: 30208470 [TBL] [Abstract][Full Text] [Related]
14. Predictors of Medication Utilization for Opioid Use Disorder Among Medicaid-Insured HIV Patients in New York. Choi S; Yerneni R; Healy S; Goyal M; Neighbors CJ Am J Addict; 2020 Mar; 29(2):151-154. PubMed ID: 31951083 [TBL] [Abstract][Full Text] [Related]
15. A comparison of buprenorphine and psychosocial treatment outcomes in psychosocial and medical settings. Presnall NJ; Wolf DAPS; Brown DS; Beeler-Stinn S; Grucza RA J Subst Abuse Treat; 2019 Sep; 104():135-143. PubMed ID: 31370977 [TBL] [Abstract][Full Text] [Related]
16. Slow release oral morphine versus methadone for opioid use disorder in the fentanyl era (pRESTO): Protocol for a non-inferiority randomized clinical trial. Socias ME; Wood E; Dong H; Brar R; Bach P; Murphy SM; Fairbairn N Contemp Clin Trials; 2020 Apr; 91():105993. PubMed ID: 32194251 [TBL] [Abstract][Full Text] [Related]
17. Opioid use disorder during pregnancy in Tennessee: expediency vs. science. Martin PR; Finlayson AJ Am J Drug Alcohol Abuse; 2015; 41(5):367-70. PubMed ID: 26186388 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of full and partial opioid agonists for opioid use disorder in outpatient settings: United States healthcare sector perspective. Choi SA; Yan CH; Gastala NM; Touchette DR; Stranges PM J Subst Use Addict Treat; 2024 May; 160():209237. PubMed ID: 38061629 [TBL] [Abstract][Full Text] [Related]
19. Buprenorphine for opiate addiction: potential economic impact. Rosenheck R; Kosten T Drug Alcohol Depend; 2001 Aug; 63(3):253-62. PubMed ID: 11418229 [TBL] [Abstract][Full Text] [Related]
20. Relative Cost Differences of Initial Treatment Strategies for Newly Diagnosed Opioid Use Disorder: A Cohort Study. Larochelle MR; Wakeman SE; Ameli O; Chaisson CE; McPheeters JT; Crown WH; Azocar F; Sanghavi DM Med Care; 2020 Oct; 58(10):919-926. PubMed ID: 32842044 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]